How DermTech Could Change Skin Cancer Testing -- Or Fizzle Out
DermTech (NASDAQ: DMTK) is trying to redefine the process for identifying skin cancer. The current approach involves a visual inspection and an invasive biopsy -- a highly inaccurate method that most patients don't like. DermTech's products help consumer avoid worrying about accuracy or surgery. While there are many risks for this $1 billion business, DermTech has immense potential to grow and become the new standard of care, rewarding patient shareholders handsomely.
DermTech created PLA, a small patch that is easy to use, accurate, and noninvasive. It's placed on the skin in question for a few seconds, then sent to the company's commercial lab for precise analysis. Within 72 hours, DermTech sends a physician report to the patient's doctor to take the next steps.
Image source: Getty Images.
Source Fool.com
